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Preterm birth, birth prior to 37 weeks gestation, is the leading cause of neonatal mortality 
and morbidity worldwide. While the uterine cavity and amniotic fluid largely remain sterile 
throughout gestation, bacterial infections can occur and are associated with preterm birth and/or 
preterm premature rupture of the fetal membranes (PPROM). Sneathia amnii can be detected as 
a component of the vaginal flora in healthy women; however, it’s also associated with bacterial 
vaginosis and preterm birth. Sn35, an isolate of S.amnii, was identified and sequenced through 
the Vaginal Human Microbiome Project at VCU. Our objective was to classify potential 
 
 
virulence determinants in Sn35 and we successfully identified a putative zinc endopeptidase. The 
zinc endopeptidase appeared to cleave itself in a site-specific manner under calcium-depleted 
conditions, resulting in a truncated protein. The truncated protein did have collagenase activity 
and bacteriolytic activity as well.  
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Chapter 1  
Introduction  
 
 
 
 
Clinical Significance of Preterm Birth  
 Preterm birth, defined as birth prior to 37 weeks gestation, is the leading cause of 
neonatal morbidity and mortality worldwide (Jefferson, 2012; Wiktin, 2014). The clinical 
definition of preterm labor is regular contractions that are accompanied with cervical change in 
less than 37 weeks gestation and is now believed to be a syndrome that is initiated by multiple 
routes (Goldenberg et al., 2008). Preterm birth can occur where labor is induced or infant is 
delivered through C-section, spontaneous preterm labor while fetal membranes are intact, or 
preterm premature rupture of the membranes, PPROM (Goldenberg et al., 2008). It is associated 
with 70% of neonatal death, 75% of neonatal morbidity and 50% of long-term neurological 
sequelae (Lacovidou et al, 2010; Whidbey et al., 2013). Classifications of preterm birth are as 
follows; extremely preterm is defined as birth after 20 weeks gestation but before 28 weeks of 
completed gestation, very preterm is defined as birth after 28 weeks but before 32 weeks of 
completed gestation, and moderate preterm is defined as birth after 32 weeks but prior to 37 
weeks (Lawn et al., 2010). There are multiple physical risk factors associated with preterm birth 
including: tobacco and drug use, carrying multiples, uterine abnormalities, extremes in maternal 
age, systemic and/or intrauterine infections, bacterial vaginosis, and cervical length (Ganu et al., 
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2012; Romero et al., 2006;  Stout et al., 2013;Wen et al., 2013). The greatest risk factor for 
preterm birth is having had a previous preterm birth (Jefferson, 2012). Non-physical factors that 
are associated with preterm birth are low socioeconomic status and race (Fettweis et al., 2014; 
Goldenberg et al., 2008) 
The annual cost of health care associated with premature birth in the United States was at 
minimum $26 billion in 2005, and in 2004 12.5% of births in the U.S. were preterm (Behrman et 
al., 2007; Hyman et al 2013).  While the U.S. is a developed country with modern medicinal 
technology, it currently holds a higher rate of preterm birth than the average rate, 7.5%, for 
developed countries and has an equal rate of preterm births with countries that are least 
developed. Additionally, within the U.S., African American women have an increased risk of 
delivering preterm; 18.4% of African American women delivered preterm and 11.7% of non-
Hispanic white women delivered preterm.  
 
Intrauterine and Amniotic Cavity Invasion by Vaginal Bacteria  
 While preterm birth is caused by a multitude of factors, between 25-40% of preterm 
births are caused by intrauterine infection and inflammation (Wen et al., 2013; Rubens et al., 
2010; Gravett et al., 2010). There is strong evidence supporting that infection induces preterm 
birth; experimental infection or LPS injection in mice has been shown to induce preterm birth, 
intrauterine infections among women correlates with preterm birth, systemic infections among 
women is associated with preterm birth and chorioamnionitic tissue isolated from women who 
had spontaneous labor at less than 30 weeks were infected with bacteria (Hirsch et al., 1995; 
Schantz-Dunn et al., 2009; Goldenberg et al., 2000; Hillier et  al., 1988).  Pregnant women with 
systemic malaria infections were shown to have inflammatory responses that correlate with 
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preterm birth; however, it has been shown that the majority of preterm birth is due to bacterial 
intrauterine infections (Jefferson, 2012; Romero et al., 2001). The accepted theory is that vaginal 
bacteria ascend through the cervix to cause infection and inflammation (Jefferson, 2012). 
Chorioamnionic tissue sampled from women undergoing C-section for spontaneous labor 
indicated that 75% of tissue was culture positive (Goldenberg et al., 2008; Jefferson, 2012). 
Bacteria isolated from preterm tissue and amniotic fluid has been found in the vagina as well 
(Romero et al., 1989).  While oral flora can be found in amniotic fluid, the general notion is that 
the oral species first enters the vagina through oro-genital contact and then begins ascension in 
the uterine cavity to invade the amniotic cavity rather than hematogenous spread (Figure 1.1) 
(Jefferson, 2012; Kim et al., 2009). The association of bacterial vaginosis, otherwise known as 
BV, and preterm birth therefore is not likely due to vaginal pathology, but ascension of BV-
associated bacteria from the vagina into the uterine cavity (Jefferson, 2012). 
 During gestation, the cervical mucus plug becomes more viscous due to the presence of 
progesterone to form a mechanical barrier. Additionally, alpha and beta defensins, antimicrobial 
compounds like lactoferrin, secretory IgA, and host immune system factors like complement are 
present within the cervical mucus plug (Jefferson, 2012). Once bacteria have crossed the cervical 
mucus plug, they can remain in the choriodecidual space or invade the chorion, cause 
chorioamnionitis, traverse the fetal membranes or enter the amniotic cavity and  are capable of 
eliciting a chronic infection that results in an inflammatory host response which can lead to 
preterm birth (Goldenberg et al., 2000; Jefferson, 2012). Triggering the inflammatory response 
mediates the release of tumor necrosis factor alpha (TNF-α), IL-6, IL-8, IL-1a, IL-1b and 
granulocyte colony-stimulate factor (Estrada- Guiterrez et al 2010; Goldenberg et al., 2000; 
Jefferson, 2012).  The release of the cytokines stimulates secretion of other cytokines,  
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Figure1.1: Schematic representation of bacterial ascension into the amniotic cavity. 
Bacterial ascension occurs at the vagina where select bacteria are able to traverse the fetal 
membranes and enter into the amniotic cavity to cause infection. Adapted from (Kim et al., 
2009) and reproduced with permission of publishing journal.  
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prostaglandins, matrix metalloproteinases, which weaken the fetal membranes and eventually 
lead to PPROM.  
 Therefore it is hypothesized that bacteria that contain certain virulence factors can 
contribute to preterm birth and/or PPROM.  The most frequently isolated BV-associated bacteria 
accompanying infection and preterm birth are Mycoplasma hominis, Ureaplasma urealyticum, 
Gardnerella vaginalis, Sneathia amnii, and Bacteriodes (Goldenberg et al., 2000; Goldenberg et 
al., 2008; Jefferson, 2012). Since numerous bacteria associated with microbial invasion of the 
amniotic cavity (MIAC) are difficult to culture, the utilization of molecular techniques, like PCR, 
has aided research of bacterial species that are present in amniotic fluid and fetal membranes 
(Goldenberg et al., 2008).  
   
Bacterial Vaginosis  
 Bacterial vaginosis, otherwise known as BV, is a complex polymicrobial disorder that is 
caused by a chemical and biological imbalance in the normal flora of the vagina. The virulence 
factors associated with BV are poorly understood and it is frequently misdiagnosed as 
trichomoniasis or a yeast infection. BV is associated with an overgrowth of commensal 
anaerobic bacteria where none is the clear pathogen. It is the most common vaginal infection 
worldwide and affects 29% of women in the United States (Allsworth et al., 2007; Fluery, 1981). 
It is associated with preterm birth, low birth weight, increased risk of acquiring HIV-1 and other 
sexually transmitted disease, pelvic inflammatory disease, and post-operative infections 
(Allsworth et al., 2011; Lambert et al., 2013; Lamont et al., 2011; Madden et al., 2012; 
Schellenberg et al., 2012). While the etiology is unknown, risk factors for BV include; race, 
douching, IUDs, and sexual activity (Madden et al., 2012).  
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 BV is characterized by a decrease in Lactobacillus species, particularly those that are 
able to produce hydrogen peroxide; the depletion of Lactobacillus allows for an increase in 
anaerobic bacteria (Muzny et al., 2013). Lactobacillus spp are gram positive rod shaped 
bacterium that are facultative anaerobes and are the primary colonizer of the vagina. In addition 
to producing hydrogen peroxide, which inhibits the growth of other bacterial species, 
Lactobacillus produce lactic acid by fermentation lowering the overall pH (< 4.5) of the vagina 
to favor the vaginal microbiota composition towards acidophiles (Fettweis et al., 2012). A shift 
in Lactobacillus composition allows for anaerobic bacteria like Gardnerella vaginalis, 
Prevotella bivia, Mycoplasma hominis, Mobiluncus spp., Atopobium vaginae, Fusobacterium 
spp., and Sneathia amnii to flourish (Harwich et al., 2012; Munzy et al., 20113).   
Research has indicated that race plays an important role for BV and consequently preterm 
birth. While 10-20% of Caucasian women experience BV, African American women have a 30-
50% rate. This racial disparity is also seen in preterm birth; African American women have a 
twofold increased risk of experiencing preterm birth and a threefold risk of extremely preterm 
birth (Sobel, 2005). While both races are colonized by Lactobacillus, there is a difference in 
colonization that attributes to BV and preterm birth. There are six species of Lactobacillus that 
colonize the vagina; Lactobacillus crispatus, Lactobacillus iners, Lactobacillus jensenii, 
Lactobacillus gasseri, Lactobacillus vaginalis and Lactobacillus johnsonii (Fettweis et al., 2014; 
Jefferson, 2012). These species of Lactobacillus vary in their stability and their ability to protect 
the vagina from BV associated bacterial colonization (Tamrakar et al., 2007). More stable 
species are not easily displaced from changes in pH, hormonal changes, nutrient sources and 
semen deposition. Women of European decent are predominantly colonized with L. crispatus, 
which is more stable and protective against BV. Women colonized with L.crispatus have a 
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fivefold decreased risk of developing BV.  African American women however, tend to be 
colonized with L.iners which is less stable and less protective than L.crisptaus and therefore 
women colonized with L.iners have a tenfold increased risk of developing BV (Fettweis et al., 
2014; Verstraelen et al., 2009). Furthermore, African American women have a higher diversity 
of microflora that is associated with microbial invasion of the amniotic cavity and preterm birth 
(Fettweis et al., 2014).  
Another associated risk factor of BV is douching, since it mechanically causes an 
imbalance in normal flora through physical and chemical irritants; douching solutions often 
contain surfactants that lyse the normal flora and allow for other bacterial growth. Additionally, 
the use of intrauterine devices is a risk factor for BV. It is thought that the presence of the IUD 
string in the vagina allows for colonization of anaerobic bacteria associated with BV (Madden et 
al., 2012). Finally, for reasons not completely understood, having multiple sex partners increases 
the risk for BV especially women who have sex with women, WSW, have a higher BV 
prevalence than women who do not (Koumans et al., 2009; Munzy et al., 2013).  
Clinical diagnosis of BV is done either by the Amsel criteria or by the Nugent scoring 
system. For the Amsel criteria, three of the four criteria characterizes a positive diagnosis of BV: 
a thin, homogenous grey-white discharge; pH greater than 4.5; presence of clue cells on wet 
mount; positive whiff amine test where a fishy smell is present with 10% KOH is added to 
sample of discharge (Amsel et al., 1983; Jefferson, 2012; Srinivasan et al., 2012). The Nugent 
system utilizes the gram stain, which is the gold standard of BV diagnosis (Srinivasan et al., 
2012). The scoring system is based on the presence of lactobacilli, curved rods and small gram 
negative rods (Nugent et al., 1991). In the majority of cases, women who test positive for BV are 
asymptomatic, so it is unclear why or what factors promote symptoms (Srinivasan et al., 2012). 
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Treatment for BV includes either oral or topical administration of clindamycin or metronidazole; 
however, relapse among women is very high (Hay, 1989; Srinivasan et al., 2012). This complex 
polymicrobial syndrome includes many species of bacteria, like Sneathia amnii, that play a role 
in both vaginal and gestational health.  
 
Sneathia amnii strain Sn35 
 Sneathia amnii, formerly classified under Leptrotrichia, is an anaerobic gram negative, 
non-motile bacterium that is part of the normal urogenital flora of women (Harwich et al., 2012). 
This species, however, is associated with serious medical complications such as; preeclampsia, 
spontaneous abortion, bacterial vaginosis, preterm birth, preterm premature rupture of the fetal 
membranes and post-partum bacteremia in both mother and neonate (Bachy et al., 2011; 
Harwich et al., 2012). The uterine cavity and amniotic fluid are thought to remain sterile 
throughout gestation; however bacterial infections can occur and S.amnii is frequently isolated 
from the amniotic cavity. (Harwich et al., 2012) S.amnii infiltration of the fetal membranes and 
amniotic cavity can lead to chorioamnionitis and/or amnionitis (Han et al., 2009). Other studies 
have shown that Sneathia colonization of the male urogenital tract can occur, suggesting that this 
organism can be sexually transmitted (Nelson et al., 2010). Additionally, through the Vaginal 
Microbiome Project at VCU, mid-vaginal isolates of 736 women were sequenced and Sneathia 
was found to be present in 43.4% of women with an abundance threshold of 0.1% of total reads 
(Harwich et al., 2012). S.amnii is a fastidious bacterium that requires blood or human serum for 
growth. Growth can occur on chocolate agar and BHI agar with supplemented blood; however it 
cannot survive on Brucella Sheep’s blood agar, making this organism human specific (Harwich 
et al., 2012).   
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 Strain Sn35, a mid-vaginal isolate, was from an African American woman in her early 
20’s enrolled in the Vaginal Microbiome Project at VCU who had extremely preterm birth at 26 
weeks (Harwich et al., 2012; Fettweis et al., 2011). Sequencing and identification was done 
using the V1-V3 regions of the 16S rRNA gene and was shown that S.amnii has high homology 
to another vaginal bacterium, Sneathia sanguinegens; which often co-occurs in the vagina 
(Harwich et al., 2012). Sneathia amnii has the smallest genome of the Fusobacteriaceae family 
with a genome size of approximately 1.34 Mbp and has 28% GC content. S.amnii has 1,282 
protein encoding genes, making up 92% of the genome and has at least 110 overlapping genes 
(Harwich et al., 2012).  
With scanning electron microscopy, S.amnii was found to have a variety of 
morphologies; it has been seen as a long rod, short rod, and both amorphous rods and cocci. The 
shorter morphologies have been identified in other bacterial species such as, Streptococcus 
monilformis and are referred to as “L forms” where the cell wall is deficient (Dienes, 1947). “L 
forms” of S.amnii were typically found in older cultures and active cultures were dominated by 
bacillus (Harwich et al., 2012).  Occasionally, the rod shaped bacterium exhibits bulbous 
protrusions at the ends of the rods (Harwich et al., 2012).  
 Preliminary research on Sneathia amnii identified that it has weak alpha hemolysin 
activity, and has the ability to ferment glycogen, maltose and glucose while is unable to ferment 
starch, mucin, galactose, sucrose or fructose (Harwich et al., 2012). Similar to other pathogenic 
bacteria, S.amnii does not have enzymes necessary for synthesis of most amino acids; however, 
it does have enzymes required to convert L-amino acids to D-amino acids and the enzymes 
necessary for the conversion of L-aspartate to fumarate, L-asparagine and oxaloacetate. 
Additionally, genes required for de novo amino acid biosynthesis have not been identified in the 
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species; however, salvage pathways for purine and pyrimidine synthesis are present (Harwich et 
al., 2012). A putative DNA restriction modification system was identified; however, it lacks a 
complete system of genetic competence (Harwich et al., 2012). Furthermore, the sequence of 
S.amnii identified a putative Type II secretion system, and has genes related to ion transport and 
multi-drug/lipid/protein pumps (Harwich et al., 2012).  
 While most gram negative bacteria are inherently vancomycin resistant, Sneathia amnii is 
vancomycin sensitive. It is also sensitive to metronidazole, a common drug used to treat bacterial 
vaginosis; however it is resistant to nafcillin, ciprofloxacin, and tetracycline. Women who are 
treated for BV with metronidazole during gestation still have a twofold increased risk of preterm 
birth.  During BV, biofilm formation on the vaginal epithelium can occur which can lead to 
antibiotic resistance; S.amnii can become resistant or tolerant of antibiotic measures if associated 
with a biofilm (Harwich et al., 2012; Swidsinski et al., 2008). While this species is part of the 
normal urogenital microflora of women little is known about this organism; however, Sneathia 
amnii seems to be a significant opportunistic pathogen that plays a role in vaginal health, MIAC, 
and preterm birth.  
 
Research Objectives 
 Sneathia amnii is part of the vaginal normal flora; however, it has serious clinical 
implications such as bacterial vaginosis and preterm birth. Since bacterial vaginosis is a risk 
factor for preterm birth and the greatest risk factor for preterm birth is having previously had 
preterm birth, it is essential to understand the ability of species like S. amnii to play a part in both 
clinical pathologies. Additionally, most extreme preterm births arise from intrauterine infections 
and inflammation and pose a more serious threat to the neonate. While Sneathia amnii can be 
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found in 25% of amniotic fluid samples of patients presenting with preterm birth, the ability of 
S.amnii to traverse the cervical mucus plug and enter into the amniotic cavity remains unknown. 
Recent studies in our lab indicating that S.amnii is cytotoxic to ME-180 cervical epithelial cells 
show a small glance of the virulence potential of S.amnii. The goal of this project is to utilize a 
Sneathia amnii mid-vaginal strain isolated from a woman who gave birth at 26 weeks to better 
elucidate details of S.amnii’s virulence determinants and its ability to traverse the fetal 
membranes. First, to characterize protease interactions with fetal membrane substrates and 
secondly, to explore bacterial ascension into the uterine cavity. These objectives have resulted in 
the characterization of a novel protease expressed by S.amnii, a potential virulence factor.  
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CHAPTER 2 
Materials and Methods  
 
 
 
 
Bacterial Strains and Growth Conditions 
 The S. amnii and E.coli strains used throughout this study are listed in Table 1. Sneathia 
amnii was maintained under anaerobic conditions at 37ºC on SBHI blood plates. SBHI blood 
plates were composed of brain heart infusion (BHI) agar (Oxoid, Cheshire, England) + 10% 
gelatin + 0.5% starch + 0.5% dextrose + 5% yeast and 10% female pooled human blood. Liquid 
media was composed of SBHI broth and pooled human serum (MP Biomedicals, Santa Ana, 
CA). SBHI broth was composed of brain heart infusion broth + 10% gelatin + 0.5 % starch + 
.5% dextrose + 0.5% yeast. After autoclaving, 10% human serum was added to the SBHI broth 
and then filter sterilized prior to S.amnii inoculation. Anaerobic conditions were met through the 
Shell Lab BacBasic Anaerobic Chamber with anaerobic gas mixture; 5% carbon dioxide, 5% 
hydrogen and 5% nitrogen.  Escherichia coli strains were grown aerobically at 37ºC on Luria-
Bertani broth (LB) agar plates containing the appropriate antibiotic. E.coli liquid cultures were 
grown in LB, incubated aerobically at 37ºC, 200 rpm.  Appropriate antibiotics were incorporated 
at the following concentrations 100µg ampicillin (Amp)/ml for E. coli, 35µg chloramphenicol 
(Cm)/ml for E. coli.  
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Table 1. Bacterial Strains  
Strain Description Source 
 
CH3 Blue  
 
 
 
Chemically competent cells 
derived from E.coli K12 
cloning strain (Amp
r
 when 
transformed with plasmid  
 
 
Bioline (Tauton, MA)  
BL21-CodonPlus (DE3)-RIL Chemically competent cells 
derived from E.coli 
Bl21(Amp
r
 when transformed 
with plasmid, Cm
r
) 
 
Bioline (Tauton, MA) 
BL21+pET32xT+peg1 BL21-CodonPlus(DE3)RIL 
cells containing peg1 from 
Sn35 in trans using pET32xT 
(Amp
r
 , Cm
r
) 
 
This study 
Sn35 Mid-vaginal isolate from 
woman in her early 20’s 
presenting with extreme 
preterm birth at 26 weeks 
Vaginal Microbiome 
Consortium, VCU 
 
Lactobacillus crispatus 
 
Mid-vaginal Isolate 
 
Vaginal Microbiome 
Consortium, VCU 
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Polymerase chain reaction (PCR) and product purification 
 For all PCR amplifications of DNA, general conditions were used with some 
modifications that were dependent upon the DNA template in use, the melting temperature (Tm) 
of the primer, and the size of the product being amplified. Reactions were composed of a 50µL 
total volume, 1 µL 10mM dNTPS, 1 µL template,1µL of both forward and reverse primer 
(10pmol dilutions in sterile water), 1µL Phire II polymerase (Thermo Scientific, Waltham, MA), 
10 µL 5X Phire buffer and 25 µL of sterile water.  Primers utilized in this study are listed in 
Table 2 and primer design was based off S.amnii isolate Sn35.  Thermocylcer reaction conditions 
were programmed as the following:  heated lid at 105 ºC, initial denaturation 99ºC for 2 minutes, 
followed by 31 cycles of denaturation at 94ºC for 30 seconds, annealing at 60ºC for 30 seconds, 
and extension at 68ºC for 2 minutes (+2 minutes, depending upon size of amplified region), and 
an additional cycle of final extension at 68ºC for 10 minutes. PCR products were then held at 
4ºC in thermocylcer or placed in -20ºC freezer  until ran on DNA gel electrophoresis and 
subsequently purified using QIAquick Gel Extraction kit (Qiagen, Valencia, CA) using 
manufacturer’s instructions.   
 
DNA Agarose Gel  
 1% DNA agarose gels were made with 1X Tris-acetate- EDTA (TAE) buffer (Life 
Technologies, Waltham, MA), agarose, and 0.15µg/mL of ethidium bromide. 5X Loading DNA 
Buffer (Bioline, Taunton, MA) was added to DNA samples for a final concentration of 1X. 
Agarose gels were electrophoresed at 124 volts in 1X TAE buffer and examined under UV light. 
The size of the product was determined against Bioline Hyperladder 1kb weight markers 
(Bioline, Taunton, MA). 
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Table 2. Primer List  
Primer Name Sequence        
PCR4TOPO T3 5 ́-ATTAACCCTCACTAAAGGGA-3 ́ 
 
PCT4TOPO T7 5 ́-TAATACGACTCACTATAGGG-3 ́ 
 
Sn35Coll2FWD 5'-GGCCGGGGATCCTTTTCAGATGCTCGTATTGATAAGAATAAAAGA-3' 
Sn35Coll2REV 5'GGCCGGCTCGAGTTATAGATACTCATAGGATTTACAATG-3' 
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Plasmid DNA purification and modification  
 Plasmid purifications were done using the QIAprep Spin Miniprep Kit (Qiagen, Valencia, 
CA) using the manufacturer’s instructions. Single colony transformants of E. coli were grown 
overnight in 3 ml LB with 100µg ampicillin/ml. Plasmid modification/ DNA manipulation 
restriction enzymes, buffers, and BSA were purchased from New England Biolabs (Ipswich, 
MA) and were used according to the manufacturer’s protocols. Plasmid restriction digests were 
done using BamHI and XhoI, and the 5’ phosphoryl groups were removed using Antarctic 
Phosphatase (New England Biolabs, Ipswich, MA) to prevent re-ligation of plasmid.  
 
Plasmid Construction 
 DNA fragments were subcloned into PCR4-TOPO (Life Technologies, Waltham, MA) 
using manufacturer’s recommended procedure and were transformed into CH3 Blue chemically 
competent E.coli (Bioline, Taunton, MA). After incubation overnight on LB agar with 
ampicillin, single colonies were selected and grown overnight in LB broth with ampicillin. 
Plasmids were purified using QIAprep Spin Miniprep Kit (Qiagen, Valencia, CA) and digested 
with New England Biolabs restriction enzymes and buffers according to the manufacturer’s 
recommendations. Digests were electrophoresed on DNA agarose gel. Bands that were the 
appropriate insertion size, based off Hyperladder 1kb (Bioline, Taunton, MA) were gel extracted 
and purified. Ligation of purified DNA fragment insert into digested pET vectors was done using 
Ready-To-Go T4 DNA Ligase and Ligase Buffer (Amersham Biosciences, Piscataway, NJ). 
Ratio used for ligation was a 3µL insert to 1µL plasmid, at 16ºC for 1 hour.  
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Transformation of chemically competent E. coli, CH3 Blues 
 A vial of chemically competent E.coli cells was thawed on ice, 3µL of pET32xT plasmid 
ligation reaction was added to the cells and reaction was incubated on ice for 30 minutes. The 
tube was placed in a 42ºC water bath for 30 seconds, immediately afterward 200µL of warmed 
SOC media (85.5mM NaCl, 2.5mM KCl, 10mM MgCl2, 2% tryptone, 0.5% yeast extract, and 
20mM glucose) was added to the reaction. The cells recovered on a shaker at 37ºC for 1 hour. 
Cells were plated on LB plates containing 100µg/mL of ampicillin.  
 
Transformation of chemically competent E. coli, BL21 DE3 RIL  
 A vial of electrocompetent E.coli cells was thawed on ice; 0.7µL of β-mercaptoethanol 
was added to the cells. The reaction was incubated on ice for 10 minutes and gently swirled 
every 2 minutes before adding 3µL of ligated plasmid and incubating on ice for 10 minutes. SOC 
media (85.5mM NaCl, 2.5mM KCl, 10mM MgCl2, 2% tryptone, 0.5% yeast extract, and 20mM 
glucose) was pre-warmed in a 42ºC water bath.  The reaction was heat pulse in a 42ºC water bath 
for 45 seconds and 250µL of warmed SOC media was immediately added to the reaction. The 
reaction was incubated for 1 hour at 37ºC, shaking at 200 rpm.  
 
Induction of BL21 DE3 RIL- Coll2 bacterial cells   
 Once plasmid was sequenced to confirm proper insertion of template into pET32xT, 
plasmid containing bacterial cells were inoculated in 6 mL overnight cultures containing LB, 
100µg/ml ampicillin (Amp) and 35µg/ml chloramphenicol (Cm) at 37ºC on shaker. The 
overnight cultures were diluted 1:200 in 1L of fresh LB containing 100µg/ml ampicillin (Amp) 
and incubated at 37ºC for 4 hours. The culture was induced with 1mM IPTG and incubated for 
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an additional 2 hours at 37ºC. Prior to induction, 500µL of the culture was collected, the bacteria 
were obtained through centrifugation. After 2 hour induction, 500µL of culture was collected, 
the bacteria were obtained through centrifugation. Uninduced and induced controls were 
electrophoresed on a NuPAGE SDS-PAGE Gel system (Invitrogen, Grand Island, NY) at 200V 
for 30 minutes in 1X NuPAGE Running Buffer. Lanes were stained with Imperial Protein Stain 
(Thermo Scientific, Waltham, MA) for 1 hour and then destained with water until bands were 
clearly visible.  Bacterial cells were collected from cultures by centrifugation at 8,000 rpm at 4ºC 
for 15 minutes. Pellets were suspended in 25 mL of 1X sterile PBS (Invitrogen, Grand Island, 
NY) and were subsequently harvested by centrifugation at 4,000 rpm at 4ºC for 15 minutes. The 
pellet was frozen at -80ºC.  
 
Polyacrylamide gel electrophoresis 
 All protein gels used the NuPAGE SDS-PAGE Gel system (Invitrogen, Grand Island, 
NY). Samples were mixed using a 30:10:4 ratio, 30 µL of sample, 10µL of Novex NuPAGE 
LDS Sample Buffer 4X (Life Technologies, Waltham, MA) and 4µL of NuPAGE Sample 
Reducing Buffer (Invitrogen, Grand Island, NY). Samples were boiled for 10 minutes and loaded 
into the wells of a NuPAGE 4-12%Bis-Tris 1.0mm Gel (Invitrogen, Grand Island, NY). Gel 
electrophoresis was for 30 minutes at 200Vs in 1X NuPAGE Running Buffer.  Gels were then 
stained with Imperial Protein Stain for one hour and destained in water until bands were visible. 
Peptide size was determined using Precision Plus Protein Kaleidoscope Standard (BioRad, 
Hercules, CA).  
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Protein Purification  
 The bacterial pellet from 1 L induction was thawed on ice and was resuspended in a 
solution of 25 mL 50mM NaP, 300mM NaCl buffer and one Complete, EDTA Free Protease 
Inhibitor Cocktail Tablet (Roche, Indianapolis, IN). The resuspended pellet was then lysed by 
passing through a  French Pressure Cell Press (Thermo Scientific, Waltham, MA) 4 times. The 
solution was then lysed by sonication on ice 6 times with 30 second sonication periods and 1 
minute rests between each pulse, bubbles were not introduced. The lysed solution was then 
centrifuged at 12,000 rpm at 4ºC for 20 minutes. The lysate was filtered with 0.45µm filter and 
immediately loaded onto a 3 mL HisPur Cobalt Resin (Thermo Scientific, Waltham, MA) 
column. After flow through collection, the column was subjected to 6 washes consisting of 10 
mL of 50mM NaP + 300mM NaCl and 10mM imidazole. Washes were collected and incubated 
on ice, wash 7 consisted of 10 mL 50mM NaP + 300mM NaCl and 20mM imidazole. Final 
elution was consisted of 3 mL of 50mM NaP + 300mM NaCl and 250mM imidazole. The Final 
elution was performed in 3, 1 mL washes where 1 mL of elution buffer was rocked gently in 
resin for 5 minutes before eluate was collected. A280 reading was collected on elute. The Eluate 
was dialyzed overnight at 4ºC against 3L of 20mM Tris-HCl pH 8.0 with 150mM NaCl using a 
3,500 MWCO Slide-A-Lyzer Dialysis Cassette G2( Thermo Scientific, Waltham, MA).  
  
Thrombin Cleavage  
 The protein was removed from overnight dialysis cassette, A280 reading was recorded. 
Thrombin CleanCleave Kit (Sigma Aldrich, St. Louis, MO) was used for removal of the purified 
protein’s Thio-HIS tag. Thrombin cleavage was performed according to the manufacturer’s 
instructions except the following deviations; 150 mM of CaCl2 was added to purified protein, 
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thrombin beads, and cleavage buffer. Cleavage reaction was rocked at 25ºC for 2 hours. The 
reaction was centrifuged at 4,000 rpm for 2 minutes; supernatant was collected and ran through 
HisPur Cobalt Resin (Thermo Scientific, Waltham, MA) column. Flow thru was collected and 
centrifuged at 4,000 rpm for 2 minutes, elute was collected.  The 3 mL final collection of 
purified protein was then diluted with 12 mL sterile water and was concentrated using Amicon 
Ultra-4 Centrifugal Filters, 30k MWCO ( Millipore, Billerica, MA) at 4,000 rpm until 500µL of 
elute remained. Thrombin cleaved purified elute was either stored at -80ºC or immediately used.  
 
Casein/Mucin/ Gelatin Zone of Activity Plates  
 General conditions were used for all zone of activity plates, with the exception of the 
substrate used; casein, gelatin from cold water fish skin (Sigma, St. Louis, MO), and mucin 
(Sigma, St. Louis, MO).  1% agarose, 1% substrate plates were made by dissolving agarose in 
1X Tris-acetate-EDTA (TAE) buffer (Life Technologies, Waltham, MA). The agarose was 
heated until boiled; substrate was added and poured in 35x10mm plates (Fisher Scientific, 
Pittsburg, PA).  After plates were solidified, 10 µL of sample were pipetted 1 inch apart. 
Samples included; 1X sterile PBS (Life Technologies, Waltham, MA), sterile water, uncleaved 
purified protein, cleaved purified protein, proteinase K (1:10 dilution, in sterile water) (Qiagen, 
Valencia, CA). Plates were placed in 37ºC incubator overnight. The plates were observed to 
identify zones of activity.  
 
Biotinylation of Collagen Type I and Collagen Type IV  
 Both collagen type IV ( Sigma Aldrich, St. Louis, MO) and collagen type I (Sigma 
Aldrich, St. Louis, MO) were from human placental tissues. Collagen types were dissolved in 0.5 
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M acetic acid to achieve 2mg/ml. Solutions were gently vortexed until completely dissolved, 
242.5 µL of 5M NaOH was added to neutralize the solutions. Appropriate calculations were 
done to identify the amount of biotin necessary for each collagen type. EZ-link Sulfo-NHS 
Biotin kit (Thermo Scientific, Waltham, MA) was used to biotinylate collagen type I and IV. 
10mM Biotin was prepared with ultrapure water; 71.9 µL of biotin solution was added to each 
collagen solution. Reaction was then incubated on ice for 2 hours. Reaction clean-up was done 
with Zeba Spin Desalting Columns (Thermo Scientific, Waltham, MA) according to the 
manufacturer’s instructions. Biotinylated collagen type I and IV were aliquoted in 100 µL in 
Siliconized Polypropylene Extended Capacity Tubes (Sigma Aldrich, St. Louis, MO) and were 
stored at -80ºC.  Dot blot was performed on biotinylated collagen type I and IV to verify 
Biotinylation. Collagen type I and IV were spotted onto Pure Nitrocellulose Blotting Membrane 
(Pall, Pensacola, FL) in 2 µL aliquots in various dilutions. Membrane was left to dry and blocked 
in 5% non-fat milk in PBS for 1 hour. Afterward 1.1 µL of Streptavidin- HRP (Thermo 
Scientific, Waltham, MA) was added to the membrane and shook for 1 hour at 25ºC.  Membrane 
was washed 3 times in 0.005% PBST and subsequently incubated with ECL Prime Western 
Blotting Detection Reagent (GE Healthcare, Buckinghamshire, UK) and developed.  
 
Collagenase Assay  
 Samples used in collagenase assay included; cleaved purified protein, 1X sterile PBS ( 
Life Technologies, Waltham, MA), 1:10 dilution Proteinase K solution ( Qiagen, Valencia, CA) 
and overnight cultures of Sneathia amnii isolate, Sn35.  Biotinylated collagen type I and IV were 
diluted to a 1:25 working concentration in 1X sterile PBS ( Life Technologies, Waltham, MA), 
10 µL of sample was incubated with collagen in Siliconized Polypropylene Extended Capacity 
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Tubes (Sigma Aldrich, St. Louis, MO) overnight at 37ºC. Samples were boiled for 10 minutes 
and were loaded NuPAGE 4-12% Bis-Tris 1.0mm Gel (Invitrogen, Grand Island, NY). Gel 
electrophoresis ran for 30 minutes at 200Vs in 1X NuPAGE Running Buffer. After 
electrophoresis, gel was rinsed with deionized water.  A 0.45µm PVDF membrane (Invitrogen, 
Grand Island, NY) was soaked in 100% methanol while sponges and Criterion Blotter Filter 
Paper (BioRad, Hercules, CA) were presoaked in 1X NuPAGE Transfer Buffer (Invitrogen, 
Grand Island, NY) with 10% methanol. Sponges, filter paper, gel and membrane were stacked 
upon one another in the Invitrogen transfer system so the arrangement was; 4-5 sponges, 1filter 
paper, gel, PVDF membrane, 1 filter paper, and finally 4-5 sponges, more sponges allowed for 
tight contact between the PVDF membrane and the gel. The transfer was run at 45V for 90 
minutes on ice in 1X NuPAGE transfer buffer with 10% methanol. Membrane was blocked 
overnight at 4ºC in 5% nonfat milk in 1X PBS and subsequently probed with 1:15,000-diluted 
Streptavidin-HRP (Thermo Scientific, Waltham, MA)  and 1X PBST ( PBS + 0.05% Tween 20) 
for 1 hour, rocking at 25ºC. The membrane was washed 3 times for 4 minutes with 1X PBST and 
developed using ECL Prime Western Blotting Detection Reagent (GE Healthcare, 
Buckinghamshire, UK), where membrane was immersed in solution for 1 minute, covered in 
plastic wrap and exposed to Blue Devil Interleaved Autoradiography Film (Genesee Scientific) 
and developed.  
 
Fibronectin assay  
 Samples were incubated with fibronectin from Human Plasma (Sigma Aldrich, St. Louis, 
MO) at 37ºC overnight. Fibronectin was diluted 1:10 with sterile 1X PBS (Invitrogen, Grand 
Island, NY) and each incubated reaction had 10µL of fibronectin. Fibronectin was incubated in a 
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variety of salt solutions; 10mM CaCl2 + 15mM ZnCl2, 15mM ZnCl2 +10 µL of cleaved purified 
protein, 2mM CaCl2 + 5mM ZnCl2, 2mM CaCl2 + 15mM ZnCl2 + 10 µL of cleaved purified 
protein, 5mM ZnCl2 +10µL of cleaved purified protein diluted 1:5, 5mM ZnCl2 +10 µL of 
cleaved purified protein diluted 1:25, 5mM ZnCl2 +10 µL of cleaved purified protein diluted 
1:125. Samples were mixed using a 30:10:4 ratio, 30 µL of sample, 10 µL of Novex NuPAGE 
LDS Sample Buffer 4X (Life Technologies, Waltham, MA) and 4 µL of NuPAGE Sample 
Reducing Buffer (Invitrogen, Grand Island, NY). Reactions were boiled for ten minutes and then 
loaded onto a NuPAGE 4-12%Bis-Tris 1.0mm Gel (Invitrogen, Grand Island, NY). Gel 
electrophoresis ran for 30 minutes at 200Vs in 1X NuPAGE Running Buffer where band size 
was determined using Precision Plus Protein Kaleidoscope Standard (BioRad, Hercules, CA).  
Gels were then stained with Imperial Protein Stain (Thermo Scientific, Waltham, MA) for one 
hour and destained in water until bands were visible. Degradation of fibronectin was evaluated 
based on complete disappearance of fibronectin peptide band, 220kDa.  
 
Laminin Assay  
 Samples were incubated with laminin from Human Placental Liquid (Sigma Aldrich, St. 
Louis, MO) at 37ºC overnight. Laminin was diluted 1:10 with sterile 1X PBS (Invitrogen, Grand 
Island, NY) and each incubated reaction had 20µL of laminin. Laminin was incubated in a 
variety of salt solutions; 10mM CaCl2 + 15mM ZnCl2, 15mM ZnCl2 +10 µL of cleaved purified 
protein, 2mM CaCl2 + 5mM ZnCl2, 2mM CaCl2 + 15mM ZnCl2 + 10 µL of cleaved purified 
protein, 5mM ZnCl2 +10 µL of cleaved purified protein diluted 1:5, 5mM ZnCl2 +10 µL of 
cleaved purified protein diluted 1:25, 5mM ZnCl2 +10 µL of cleaved purified protein diluted 
1:125. The samples were mixed using a 30:10:4 ratio, 30 µL of sample, 10 µL of Novex 
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NuPAGE LDS Sample Buffer 4X (Life Technologies, Waltham, MA) and 4µL of NuPAGE 
Sample Reducing Buffer (Invitrogen, Grand Island, NY). The reactions were boiled for ten 
minutes and then loaded onto a NuPAGE 4-12%Bis-Tris 1.0mm Gel (Invitrogen, Grand Island, 
NY). Gel electrophoresis ran for 30 minutes at 200Vs in 1X NuPAGE Running Buffer where 
band size was determined using Precision Plus Protein Kaleidoscope Standard (BioRad, 
Hercules, CA).  Gels were then stained with Imperial Protein Stain (Thermo Scientific, Waltham, 
MA) for one hour and destained in water until bands were visible. The degradation of laminin 
was evaluated based off complete disappearance of laminin peptide bands at 50 kDa and 130-
160kDa.  
 
Coagulase Assay  
 BBL Coagulase Plasma Rabbit (BD, Franklin Lakes, NJ) vials were rehydrated in sterile 
purified water; one vial was aliquoted into six separate tests. Reactions with coagulase test 
included; 1X Sterile PBS (Invitrogen, Grand Island, NY),  live overnight culture of Sneathia 
amnii isolate SN35, cleaved purified protease + 5mM ZnCl2, cleaved purified protease, 5mM 
ZnCl2,  2mM CaCl2. The reaction vials were gently mixed and incubated in 37ºC water bath. The 
tubes were examined by tipping the tube to identify clotting after 4 hours and then again at 24 
hours to identify any weak enzyme production.  
 
Turbidity Assay  
 A 2mL overnight culture of SN35 was grown and subcultured into 10mL of fresh media. 
Culture grew for 6 hours to reach exponential stage and was removed from the anaerobic 
chamber. Culture was divided into two 5mL cultures. One 5 mL culture was centrifuged at 
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4,000rpm for 4 minutes. Supernatant was removed and pellet was washed with sterile water and 
centrifuged. The pellet was resuspended in 4 mL of sterile water and aliquoted into two 2 mL 
tubes. Non-centrifuged culture was separated and aliquoted into two 2 mL tubes. The initial 
sample optical density readings, OD600nm, were determined using a spectrophotometer; sterile 
SBHIs and sterile water were used as controls. Afterward, 100µL of cleaved purified protease 
was added to 1 tube of Sn35 in SBHI media and 1 tube of Sn35 in sterile water; 100µL of 
dialysis buffer was added to other Sn35 tubes. The optical density was determined immediately, 
then after 30 minutes, 1 hour, 2 hours, and 24 hours.  
  
Collagen Type IV Biofilm Assay  
 Cell Adhesion Human Collagen Type IV Strips (Millipore, Temecula, CA) were 
rehydrated in 200 µL of 1X sterile PBS (Invitrogen, Grand Island, NY) for 15 minutes at room 
temperature; PBS was removed from the strips.  Overnight culture of Sn35 was grown and 
diluted until OD600nm was 1. The strip wells were inoculated as such; SBHI alone, 100 µL of 1:10 
dilution Sn35 OD=1, 100 µL of 1:100 dilution Sn35 OD=1, 100 µL of 1:10 dilution Sn35 OD=1 
boiled for 5 minutes, 100 µL of cleaved purified protease, 100 µL of heat killed Sn35 + cleaved 
purified protease, SBHI alone, and last lane was left as BSA. The collagen strips were kept under 
anaerobic conditions at 37ºC overnight and suspensions were discarded and well strips were 
washed gently 2-3 times with 200 µL of PBS. The wells were stained with 100 µL of safranin; 
adherence was determined by visualization of the degree of safranin staining.  
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Edman Degradation  
 The protein was purified and cleaved using methods mentioned above. Thrombin treated 
protein was run on an 4-12% Bis-Tris 0.1mm NuPAGE gel for 30 minutes at 200V. Gel was 
electroblotted onto PVDF membrane using methods mentioned previously. PVDF membrane 
was then stained using Imperial Protein Stain (Thermo Scientific, Waltham, MA) for 1 hour. The 
membrane was destained for 15 minutes using 15% methanol/10% acetic acid and was rinsed 
under deionized water for 4 hours. The band of interest was excised and placed in 
microcentrifuge tube with deionized water. Edman degradation was performed by Iowa State 
University Protein Facility; membrane was washed 6 times in deionized water and sample was 
analyzed by 494 Procise Protein Sequencer/140C Analyzer from Applied Biosystems, Inc.  
 
Bacteriolysin Assay  
 A 10% SDS PAGE separating gel containing 0.003g of dry Micrococcus luteus was 
poured, allowed to solidify and a 4% SDS PAGE stacking gel was prepared and poured on top of 
the separating gel. After the gels polymerized, cleaved purified protein was mixed with 5X 
Loading buffer and was electrophoresed at room temperature at 175V for 40 minutes in 1X SDS 
PAGE running buffer. Gels were rinsed for 1 hour under a slow stream of sterile water for one 
hour and then immersed in 100mM phosphate buffer pH 7.0 + 10mM MgCl2. Gels remained in 
buffer, rocked overnight at 37ºC. Gels were rinsed with sterile water and subsequently stained 
with Imperial Protein Stain (Life Technologies, Waltham, MA) for one hour. Gels were 
destained in sterile water until banding patterns were visible.  
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Antiserum Production  
 Cleaved purified protein (> 1.5mg/ml) was produced using methods mentioned 
previously and shipped to New England Peptides. Prior to immunization, 5 mL of pre-immune 
sera was collected from one rabbit (New Zealand White- SPF), the rabbit was  immunized with 
protein 3 times. Boosts occurred at day 14 and 28, bleeds occurred on days 35 and 40.  Upon 
arrival, sera were aliquoted into cryovials and stored at -80ºC.  
 
Antisera Detection and Subsequent Westerns with antisera 
 All western analysis performed with antisera had a positive control sample consisting of 
frozen cleaved purified protein. Samples were electrophoresed with SDS NuPAGE gel as 
previously mentioned in methods. After electrophoresis, gels were rinsed with deionized water. 
0.45µm PVDF membranes (Invitrogen, Grand Island, NY) were soaked in 100% methanol while 
sponges and Criterion Blotter Filter Paper (BioRad, Hercules, CA) were presoaked in 1X 
NuPAGE Transfer Buffer (Invitrogen, Grand Island, NY) with 10% methanol. Sponges, filter 
paper, gel and membrane were stacked upon one another in the Invitrogen transfer system so the 
arrangement was; 4-5 sponges, 1filter paper, gel, PVDF membrane, 1 filter paper, and finally 4-5 
sponges, more sponges allowed for tight contact between the PVDF membrane and the gel. 
Transfers were run at 45V for 90 minutes on ice in 1X NuPAGE transfer buffer with 10% 
methanol. Membranes were blocked overnight at 4ºC in 5% nonfat milk in 1X PBS and 
subsequently probed with anti-sera, 1:2,500 in 1X PBST( PBS + 0.05% Tween 20) for one hour; 
rocking at room temperature. Membranes were washed 4 times for 15 minutes with 1X PBST 
and then probed with 1:15,000 diluted Goat-Anti-Rabbit IgG ( H+L) Horseradish Peroxidase 
Conjugate ( Life Technologies, Waltham, MA) for 45 minutes; rocking at room temperature. 
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Membranes were washed 4 times for 15 minutes in 1X PBST.  The membrane blots were 
incubated in ECL Prime Western Blotting Detection Reagent (GE Healthcare, Buckinghamshire, 
UK) for 1 minute, covered in plastic wrap and developed with autoradiography film.  
 
Sn35 Growth Curve Assay 
 A 250 mL culture of SBHI + 10% Human Serum was inoculated with a 5 mL overnight 
culture of Sn35 under anaerobic conditions at 37ºC. At 4 hours, 100 mL of growing culture was 
collected and centrifuged at 4,000 rpm for 20 minutes. The supernatant was discarded and pellet 
was stored at -80 ºC. Additional time points of 6, 8, 12, 16, 24, and 48 hours were collected, 
centrifuged, and stored at -80º C as well. For each time point the culture collected was halved so 
that at 48 hours 1.56 mL was collected.  Pellets were resuspended in NuPAGE SDS Loading 
Buffer and boiled for 10 minutes, afterward A280 reading was performed to confirm protein 
concentration. Samples were loaded into wells so that each contained equivalent amounts of 
protein. SDS page gels were electrophoresed, transferred onto PVDF membrane and 
subsequently probed with antisera.  
 
Adhesion Binding Assay  
 A 200 mL culture of SBHI 5% human serum was inoculated with SN35 and grown 
overnight. Bacterial cells were harvested by centrifugation at 3,000g for 20 minutes at 4ºC. 
Supernatants were discarded and pellets were gently resuspended in 7 mL of TSE buffer 
(200mM Tris-HCL pH 8.0, 500mM sucrose, 1mM EDTA, protease inhibitor cocktail). Cells 
were incubated on ice for 30 minutes and then centrifuged at 16,000g for 30 minutes at 4ºC. 
Supernatants were transferred to an ultracentrifuge tube and centrifuged at 60,000g for 1 hour at 
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4ºC. The final spin pellet contained outermembrane proteins while the supernatant contained 
periplasmic proteins. Pellet was resuspended in 200 µL of TSE buffer, if not immediately used 
pellet was stored at -80ºC. Eight CellStar T75 Flasks (Greiner Bio-One, Monroe, NC) of 
VK2/E6E7 (ATCC, Manassas, VA), human epithelial vaginal mucosal cells, in 1X Keratinocyte 
Serum Free Media ( Life Technologies, Waltham, MA) accompanied with Supplements for 
Keratinocyte Serum Free Media ( Life Technologies, Waltham, MA) were prepared. Once cells 
were grown to 80-90% confluency, outermembrane cell surface proteins were biotinylated and 
extracted using Pierce Cell Surface Protein Isolation Kit (Thermo Scientific, Waltham, MA). 
Manufacturer’s instructions were followed for Biotinylation, Cell Lysis, and Isolation of Labeled 
Proteins. After the streptavidin beads were washed in final wash buffer, they were washed with 
1X sterile PBS (Life Technologies, Waltham, MA) and centrifuged at 1000g, this was repeated 3 
more times. Outer membrane surface proteins isolated from Sn35 were added to streptavidin 
beads and rocked for 30 minutes at room temperature with end-over-end rotator. Flow thru was 
collected via centrifugation at 1000g for 1 minute. The streptavidin beads were subject to a series 
of stringent washes where each wash was collected by centrifugation at 1000g for 1 minute. All 
washes were done twice and consisted of 500µL. Washes went in the following order; 10mM 
Tris-HCl pH 8.0 + 10mM NaCl, 10mM Tris-HCl pH 8.0  + 25mM NaCl + 10mM KCl, 10mM 
Tris-HCl pH8.0 + 100mM NaCl + 25mM KCl, 10mM Tris-HCl pH 8.0 + 150mM NaCl + 50mM 
KCl, 10mM Tris-HCl pH 8.0 + 150mM NaCl + 200mM KCl. The final wash was Novex 
NuPAGE LDS Sample Buffer 4X (Life Technologies, Waltham, MA). Samples, including beads, 
were boiled and run on a NuPAGE SDS gel. The gel was rinsed with sterile water, stained with 
Imperial Protein Stain for one hour and destained until band patterns were visible.  
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Placental Invasion Assay  
 Full term healthy caesarean section, c-sectioned, placentas were provided by consenting 
women who gave birth at VCU Medical Center through IRB approval #HM10906_CR1 through 
Dr. Scott Walsh. Placental tissues were immediately placed in a sterile hood using sterile gloves 
and 4cm x 4cm sections of placental tissues were cut and submerged in a solution of 1X DMEM 
( Life Technologies, Waltham, MA) and 1mg/mL Penicillin Streptomycin (Life Technologies, 
Waltham, MA) for 2 hours in Series II Water Jacket CO2 incubator (Thermo Scientific) at 37ºC. 
Sectioned tissues were washed 5 times with 1X sterile PBS (Life Technologies, Waltham, MA). 
Washed tissue sections were then placed on the outside of a 0.4µm Sterile cell Strainer (Fisher 
Scientific, Pittsburg, PA) that did not have a bottom strainer. The tissue was kept in placed with a 
sterile rubber band. Cell strainer + tissue were them placed in a 6 Well Tissue Culture Plate 
(Grenier, Nurtingen, DE). Each well had 7 mL of antibiotic free DMEM ( Life Technologies, 
Waltham, MA) and 10% pooled human serum. The 6-well plate was incubated overnight in 
BacBasic Anaerobic Chamber overnight. Live cultures of SN35 and Lactobacillus crispatus 
were inoculated into separate strainers and were left under anaerobic condition overnight. 
Placental tissues were removed from the cell strainer and were gently washed in 1X sterile PBS 4 
times. Tissues were then submerged in 4% paraformaldehyde + 2% glutaraldehyde in 0.1M 
Cacodylate Buffer. Tissues were embedded in paraffin, sectioned and mounted on microscope 
slides, and observed under light microscopy. Media from the top portion of cell strainer and the 
media at the bottom of the well were inoculated onto SBHI Blood agar plates and grown under 
anaerobic conditions, CFUs were noted.  
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ME180 Cytotoxicity Assay  
 A 6-well plate (CellStar) of human epithelial cervical carcinoma ME-180 cells (ATCC, 
Manassas, VA) were grown to 99% confluency in McCoy’s 5A Media Modified (Cassion Labs, 
Logan, UT). Cells were incubated in CO2 incubator at 37º C during growth. Wells were washed 
3 times with 1X sterile PBS (Life Technologies, Waltham, MA) and subsequently incubated in 2 
mL of 1X sterile PBS. Wells were then either inoculated with cleaved purified protease, cleaved 
purified protease + 50mM ZnCl2, 50mM ZnCl2, or 2mM CaCl2. The plates were incubated 
overnight in CO2 incubator at 37º C. Monolayers were examined via light microscopy.  
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CHAPTER 3  
Analyses of Pathogenicity Potential of Sneathia amnii isolate Sn35 
 
 
 
 
Introduction 
 
 Once bacteria have invaded the amniotic cavity; the bacterial infection is able to elicit an 
inflammatory response. Pathogen associated molecular patterns, PAMPs, are recognized by toll-
like receptors and activate the innate immune response and the production of cytokines like IL-
1α, IL-1β- IL-6, and TNF-α are stimulated (Chiesa et al., 2015; Goldenberg et al., 2008).  An 
increase in IL-6 is a hallmark of preterm birth and the fetal inflammatory response syndrome; 
while IL-6 levels are modest during term labor, they are excessively higher in preterm births 
(Chiesa et al., 2015; Romero et al., 2007).  IL-6 is produced by a variety of cells and functions to 
regulate the immune response, inflammation and the acute phase response (Chiesa et al., 2015).  
The concentration of IL-6 serves as an indicator of the severity of inflammation and if highly 
elevated levels of IL-6 exist, the fetal inflammatory response syndrome (FIRS) is activated 
(Chiesa et al., 2015; Jefferson, 2012). Furthermore, IL-6 recruits neutrophils and other 
leukocytes to the fetal membranes to secrete pro-inflammatory cytokines.  
 The activation of pro-inflammatory cytokines is a normal process during parturition and 
leads to the increased activity of matrix metalloproteinases and production of prostaglandins 
(Goldenberg et al., 2008). Throughout gestation, IL-10, an anti-inflammatory cytokine, is 
expressed to prevent premature responses; however the production of IL-10 decreases towards 
the end of gestation and allows for increased activity of other cytokines to induce labor (Hanna et 
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al., 2000).   In order for labor to occur, the cervix must soften, shorten and dilate, and the fetal 
membranes have to become weakened in order to rupture for birth. During labor estrogen, 
prostaglandins, and oxytocin hormones work together to cause the uterus to contract forcefully; 
birthing the fetus (Jefferson, 2012). The decrease in IL-10 allows for corticotropin releasing 
hormone receptor (CRH-R1) to be induced and thereby increases prostaglandin and placental 
estrogen release (Jefferson, 2012). In addition to cytokines, women with MIAC will have 
elevated amniotic fluid levels of matrix metalloproteinase-8 (Combs et al., 2014). Matrix 
metalloproteinases, MMPs, like MMP-8 and MMP-9 can degrade collagen which allows for the 
fetal membranes to weaken and aides in the onset of labor (Estrada-Gutierrez et al., 2010).  
 The fetal membranes are composed of collagens type I, III, IV and V and allow for high 
tensile strength. Collagen is the most abundant protein found in mammalian bodies and is typed 
based upon the structure it forms. Collagen type IV forms the basal lamina found in the basement 
membranes, collagen type V is found in the placenta, collagen type III is typically found with 
collagen type I which is found in organs and ligaments. The collagen in fetal membranes allows 
for resilience; however, at the end of term labor MMPs degrade collagen to induce labor. 
PPROM and preterm birth have been correlated with elevated activity of collagenases (MMP-8) 
as well as other MMPs (Maymon et al., 2001).  The increase in MMPs can be due to 
inflammation, but also bacteria. MMP-9 has elevated expression in the fetal membranes in the 
presence of bacteria. Additionally, select bacterial species are capable of producing their own 
matrix metalloproteinases in order to degrade collagen (Jefferson, 2012).  The work done on this 
study was to analyze the Sneathia amnii genome to identify MMPs that could be responsible for 
fetal membrane destruction and PPROM.  
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Results  
Invasion of human fetal membranes by Sneathia amnii 
 It has been determined that MIAC is a cause of preterm birth. Invasion of the amniotic 
cavity depends upon the bacteria’s ability to produce virulence factors to promote entry into the 
fetal membranes and cause infection.  Previous data showed that Sneathia amnii is detectable in 
the amniotic cavity and can cause chorioamnionitis and amnionitis leading to preterm birth 
(Harwich et al., 2012). Therefore it is thought that Sneathia amnii is ascending from the vagina 
and ultimately flourishing in the amniotic cavity. Placental tissues from full term healthy c-
sectioned patients were incubated with isolate Sn35 in anaerobic conditions at 37ºC to mimic the 
in vivo environment. We found that placental tissues incubated with Sn35 had extensive damage 
to the chorion layer causing the cells to round up (Figure 3.1) .Additionally, tissues incubated 
anaerobically with no bacteria saw no damage to the chorion layer; however, tissue incubated 
with Sn35 no longer had tight cell to cell contact.  This observation supported previous 
hypothesis of bacterial ascension and additionally these results determined that Sn35 can invade 
the placental tissues over a short amount of time. However, media plated from the bottom 
portion of the well did not have any microbial growth from either Lactobacillus crispatus or 
Sn35, suggesting that the bacteria did not traverse the fetal membranes within 24 hours. While 
media plated from the top of the cell strainer did have colony growth suggesting that the bacteria 
survived the experimental conditions. Previous results suggest that L.crispatus does not traverse 
the fetal membranes. The media plated from the top was to ensure that bacterial survival could 
occur in DMEM 10% Human serum. The lack of Sn35 in the bottom portion of the well 
indicated that while Sn35 has the ability to traverse the first layer of the fetal membranes, it may 
need additional time to fully traverse the fetal membranes.   
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Figure 3.1: Fetal membranes incubated with or without Sn35.  Placental tissue not incubated 
with bacteria (top image) remained intact and did not have cell or tissue damage. Placental tissue 
incubated with Sn35 (bottom image) had extensive tissue and cell damage. Highlighted in the  
box, the chorion layer no longer possessed tight cell:cell contact and cells appeared to be 
rounding; indicating that Sn35 was able to traverse the chorion layer.  
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Sn35 adhesion capability with VK2 cell line  
 Bacterial adhesion to a eukaryotic cell always precedes invasion. In order to identify 
ligand: ligand receptor interaction, outermembrane proteins from both Sn35 and VK2 cells were 
isolated. VK2 outermembrane proteins were biotinylated and bound to streptavidin beads while 
outermembrane proteins from SN35 were added to the VK2 beads. A series of stringent salt 
solutions was used to wash the beads in hopes of identifying a bacterial peptide with high affinity 
for a eukaryotic protein. However, we did not detect a peptide that remained on the streptavidin 
beads following the initial washes. Therefore we did not isolate a Sn35 adhesin. 
 
Selection of virulence determinant expressed by Sn35 
 Bioinformatic analysis revealed a gene of interest in Sn35 labeled as a putative zinc 
endopeptidase with homology to the M23 peptidase family comprised of glycine glycine 
endopeptidases and matrix metalloproteinases.   Analysis using SignalP4.1 suggested that the 
putative zinc endopeptidase had a signal peptide for secretion via the sec pathway. The 
isoelectric point of the putative zinc endopeptidase is 10.63 pH(I). With the signal peptide, the 
gene is 1311 bp and  436 amino acids and is 48.95 kDa .Additionally, it also has an active site 
characteristic of the M23 peptidase family, HXXXD, where HXXXD is HAILD, and is found 
AA site 165-169 (Figure 3.2) This putative gene was of interest to our research since it could be 
a potential virulence determinant that allows Sn35 to traverse the fetal membranes .The zinc 
endopeptidase gene, without its signal sequence, was then amplified by PCR with specific 
primers, and was named protein encoding gene 1 (Peg1). Serial cloner indicated that the gene is 
1233 bp (Figure 3.3).   
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ATG AAA ATA ACT GGG AAG TGT AGT GTA TTA CTT CTT TCA TTA GCA CTC TCT ATA 
  M   K   I   T   G   K   C   S   V   L   L   L   S   L   A   L   S   I  
                                                                        18 
 
   
CCA TAT ATG ACA TTT TCA GAT GCT TTT TCA GAT GCT CGT ATT GAT AAG AAT AAA 
  P   Y   M   T   F   S   D   A   F   S   D   A   R   I   D   K   N   K 
                                                                        36 
   
 
AGA AGA ATA GCA CAA ATA AAT AGA CAA GTT ACA CAA AAC AGA AAT CTT ATT ATA 
  R   R   I   A   Q   I   N   R   Q   V   T   Q   N   R   N   L   I   I    
                                                                        54 
 
   
AAA AAC AAT AGA CAA ATT GTT GTT ACT AAA AGA ACA CAA GCA AGT TTA CAA TCA  
  K   N   N   R   Q   I   V   V   T   K   R   T   Q   A   S   L   Q   S    
                                                                        72 
 
 
GAA ATC AAT GAC TTG AAT TTT CAA ATT AAC AAG CTA CAA AAA GAA TAT AAT GTT  
  E   I   N   D   L   N   F   Q   I   N   K   L   Q   K   E   Y   N   V    
                                                                        90 
 
 
CTA GAA CAA AGA TAT ATA GAA CTA TTA AAA GCA ATT GGA GCT AAT GAA AAA GAT  
  L   E   Q   R   Y   I   E   L   L   K   A   I   G   A   N   E   K   D    
                                                                       108 
 
 
ATT AAA GCA TCA ATT TCT AAA ATT CAA AGT AGT AAT GCT GAA ATA AAA GTT AAT 
  I   K   A   S   I   S   K   I   Q   S   S   N   A   E   I   K   V   N    
                                                                       126 
 
 
AAA GAT GAA TAT AAC ACA AAG ATA AGA AAT TAT GAT TTA ATT AGA AGA GCA AGA 
  K   D   E   Y   N   T   K   I   R   N   Y   D   L   I   R   R   A   R    
                                                                       144 
    
 
AAT ATT AAT CAA AAT AGT GGT TTA GTT GGT GCA AGA CGT GAT AAA TTA AGA CAC 
  N   I   N   Q   N   S   G   L   V   G   A   R   R   D   K   L   R   H                                        
                                                                       162 
 
 
GAT GCA CAT GCT ATA CTA GAC CTA CAA ATC AAT AAA ATA AAG GGC ATA GAG ACA  
  D   A   H   A   I   L   D   L   Q   I   N   K   I   K   G   I   E   T 
                                                                       180      
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TAT AAA AAA GGT GTA GAA CAA GAT AAG ATT AAG GTT GAA GGA ATA AAA CAA AAG 
  Y   K   K   G   V   E   Q   D   K   I   K   V   E   G   I   K   Q   K    
                                                                       198 
 
 
AAT CAA TCT GAA GCT ACT AAA GTT ATG AGT GCT AGA AAT GAT TTA GAA AAT AAG  
  N   Q   S   E   A   T   K   V   M   S   A   R   N   D   L   E   N   K 
                                                                       216 
   
 
AAG AAA GAA CTT AAT ACT GCT GTT GCA AGA AAG AAT AAA GCA GTA GCT GAA TTA  
  K   K   E   L   N   T   A   V   A   R   K   N   K   A   V   A   E   L 
                                                                       234 
 
 
AGA GAC TTA CAA AAT AAA TTA AGA AAA GAA AAT ATT ACT ATT GAA AAA AAT AAT  
  R   D   L   Q   N   K   L   R   K   E   N   I   T   I   E   K   N   N   
                                                                       252 
 
 
AGT AAA TTA GCT TCT GAA AGA AAT AGA TTA GAA GCA CAA ATT AAT GCA ATT ATA  
  S   K   L   A   S   E   R   N   R   L   E   A   Q   I   N   A   I   I    
                                                                       270 
 
   
CGA CAA AAT GCA ATA AGA CAA CAA CAA CTT GAA AGA CAA AGA CAA TTA GCA TTA 
  R   Q   N   A   I   R   Q   Q   Q   L   E   R   Q   R   Q   L   A   L  
                                                                       288 
 
   
CGT CGT AAA CAA CAA CAA GGT TCT GCT AAA CAT GAA AAT ATA AAT GTT TCA CAA 
  R   R   K   Q   Q   Q   G   S   A   K   H   E   N   I   N   V   S   Q    
                                                                       306 
 
   
GAA CCA ATA AAT GTT GTA AAA GGA ACT GGA TCA TTA ATT TAT CCT ATT AGA GGT 
  E   P   I   N   V   V   K   G   T   G   S   L   I   Y   P   I   R   G    
                                                                       324 
 
 
AGG GTA GTT GTA GGA TTT GGT ACT GAA AAA GTT CAA GGA TTA AAG AGT AAA GGT  
  R   V   V   V   G   F   G   T   E   K   V   Q   G   L   K   S   K   G    
                                                                       342 
     
   
ATA GAA ATA TTA GGT ACA TTA GGT CAA TCT GTA TCT GCT GCT GAT ACT GGA ACT 
  I   E   I   L   G   T   L   G   Q   S   V   S   A   A   D   T   G   T 
                                                                       360 
 
 
GTA ATA TAT TCA GGA AGT CTT GGA GGA TTA GGA AGA GTT GTA ATA ATA AGC CAC 
  V   I   Y   S   G   S   L   G   G   L   G   R   V   V   I   I   S   H 
                                                                       378 
   
39 
 
 
GGT TCA CTA ATT ACA GTT TAT GGT AAT TTA GCA TCT ATA AGG GTA TCA AGA AAT 
  G   S   L   I   T   V   Y   G   N   L   A   S   I   R   V   S   R   N 
                                                                       396  
 
 
GAA GCT GTT CGT AAA GGA CAA AGT ATA GGA ACT TTA GGA AGA GAT TCT GAA ACT                
  E   A   V   R   K   G   Q   S   I   G   T   L   G   R   D   S   E   T 
                                                                       414 
 
   
AAG AAA CCA ACA CTT TAC TTT GAA GTT AGA CAT GGT GTT AAC ATT GTA AAT CCT 
  K   K   P   T   L   Y   F   E   V   R   H   G   V   N   I   V   N   P   
                                                                       432 
 
  
ATG AGT TAT CTA TAA        
  M   S   Y   L   * 
                   436 
 
 
 
 
 
 
 
 
 
Figure 3.2 Gene Map of Putative Zinc Metalloprotease. The nucleotide sequence is shown 
first and the amino acid sequence is directly below it. The number, seen at the end of every line, 
correlates to the position of the last amino acid on the line. The signal peptide is highlighted in 
green, the active site HAILD is highlighted in blue, and the M23 peptidase is highlighted in 
orange.  
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Figure 3.3: DNA gel of Peg1 PCR amplification.  PCR amplification of Peg1 was done using 
Peg1 specific primers.  Lane 1 (left most lane) contains Hyperladder 1kb, Lane 2 contains PCR 
product Peg1, 1123kb which is highlighted in the box. Molecular weight markers indicated.  
DNA sequence of Peg1 is noted below DNA gel.  
 
 
 
 
 
 
 
 
1500 bp 
1000 bp 
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Expression and purification of recombinant Peg1  
 Peg1 was cloned into pET32xT (generously donated by Dr. David Williams, VCU, 
Richmond, VA) in BL21 DE3 RIL E.coli cells, clones were restriction digested (Figure 3.4) and 
sequenced to ensure successful cloning. The vector, pET32xT, is an IPTG inducible vector  
which attached a C-terminal Thio-HIS tag to the protein. Expression of the Thio-His-tagged 
Peg1 product was confirmed through SDS PAGE gel with the presence of the protein at 
approximately 64.1kDa upon induction with 1M IPTG (Figure 3.5).  Peg1 is 46.1kDA while the 
His-tag is 18kDA. The expressed recombinant protein was isolated through column purification 
using cobalt resin (Figure 3.6) and the Thio-His tag was removed by thrombin cleavage and the 
addition of calcium (Figure 3.7). If 150mM of CaCl2 was not added to the thrombin cleavage 
reaction, Peg1 rapidly degraded in a site specific fashion leaving two peptide bands at 35kDa and 
12kDA (Figure 3.8).  The degradation appeared to be autocatalytic as no contaminating proteases 
were detected. While Peg1 does not have an obvious (HEXXH) zinc binding motif, which is 
common in M23 peptidases, our results determined that CaCl2 does hinder Peg1’s autocatalytic 
degradation. Additionally, these results determined that the protein degrades itself in a site 
specific manner to produce a C-terminal peptide and an N-terminal peptide. 
 
Edman Degradation  
 Site specific cleavage is also seen in a zinc endopeptidase expressed by Bacteriodes 
fragilis (Freer et al., 1999). The protein is cleaved into a proprotein and a mature protein between 
an Arginine (211) and Alanine (212). We hypothesized that since Sneathia amnii is also a zinc 
metalloprotease, Peg1could cleave itself at the same motif. Sn35 has an Arginine Alanine site 
where if cleaved at this site it would produce a protein around 35 kDa. However, when the 
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Figure 3.4F: DNA agarose gel analysis of restriction digest of BL21 DE3 RIL E.coli cells 
containing pET32xT+Peg1.  Lane 1 contains HyperLadder 1kb, lane 2 contains BL21 DE3 RIL 
colony miniprep that has been digested with BamHI and XhoI. The fragments 5900 bp 
(pET32xT) and 1123 bp (Peg1) indicate successfully cloning by restriction digest confirmation.  
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Figure 3.5: Confirmation of induced Peg1 with 1mM IPTG.  Imperial stained SDS-PAGE of 
uninduced (Lane 2) and induced (Lane 3) cell lysates of E.coli BL21 DE3 RIL cells containing 
pET32xT+ Peg1. Molecular weight markers are shown above. Peg1 with Thio-HIS tag is 64.1 
kDa, indicated in box, is induced under IPTG.  
 
 
 
 
 
 
 
 
75 kDa 
50 kDa 
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Figure 3.6:  Purified protein by cobalt resin column confirmed with SDS PAGE.  Lane 5 
indicates purified protein was collected after 250mM imidazole wash, peptide band boxed in is 
Peg1 which is 64.1 kDa. Molecular weights are indicated. Lane 2 is flowthrough, Lane 3and 4 
are 10mM imidazole washes.  
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Figure 3.7: Thrombin cleavage of Thio-HIS tag with CaCl2.  SDS-PAGE gel shows 
supplementation of CaCl2 in the thrombin reaction allowed for recovery of 46.1 kDa peptide, 
boxed in Lane 2. Molecular weight markers are noted.  
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Figure 3.8: Thrombin cleavage without CaCl2 allows for site specific degradation.  Imperial 
stained SDS PAGE gel depicts autodegradation of Peg1 into 2 peptides sized 12 kDa and 37 kDa 
in Lane 3. Lane 2 is thrombin treated Peg1. Molecular weight markers are indicated.  
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11.98 kDa peptide was sent for N-terminal sequencing, it was found that Peg1 cleaves itself 
between a Glutamine (335)  (Q) and Glycine (336)   (G) before a Leucine Lysine (LK) 
motif leaving the N-terminal peptide at 312 AA and the C-terminal peptide at 92 AA (Figure 
3.9). The N-terminal peptide is 34.12 kDa while the C-terminal peptide is 11.98 kDa.  
 
 
Extracellular Matrix Component Degrading Activity 
 We hypothesized that Peg1 would be able to degrade a substrate that was present in the 
fetal membranes. First, the protease was tested against a universal protease assay where casein 
acted as the substrate. Zone of activity plate assays indicated that proteinase K, a broad spectrum 
serine endopeptidase, was able to degrade casein; however, Peg1 was unable to degrade casein. 
This same method was tested with gelatin and mucin and the results were the same, proteinase K 
was able to degrade the three substrates while Peg1 was unable to. Mucin was tested as a control 
since it was already shown that Sn35 was unable to degrade mucin (Harwich et al., 2012).  
Since Blastx indicated homology to matrix metalloproteinases, we next hypothesized that 
the substrate of Peg1 would be a component in the extracellular matrix. The ECM consists of 
extracellular molecules secreted by cells that allow for structural support for the surrounding 
cells, tissues repair, and intercellular communication. Matrix metalloproteases, serine proteases 
and threonine proteases aide in the dynamic changes of the ECM by degrading and remodeling 
the ECM. The ECM components include collagen, fibronectin and laminin. Fibronectin is a 
glycoprotein that binds to integrins, fibrin, collagen and proteoglycans and allows for dynamic 
movement; it is an insoluble matrix where its monomers are linked together by disulfide bonds. 
While laminin, a major extracellular matrix protein of the basal lamina aides in cell adhesion and  
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Signal Peptide                                       N-terminus                                          Q  G                  C-terminus  
(1-22)                                      (23-334)                                     335 336             (337-430) 
2.64 kDa               34.12 kDa                     11.98 kDa  
           
 
 
 
MKITGKCSVL        
LLSLALSIPYMT           
             
          GLKSKGIEILGTLGQS 
VSAADTGTVIYSGSLG 
GLGRVVIISHGSLITVY 
GNLASIRVSRNEAVRK 
GQSIGTLGRDSETKPTL 
            YFEVRHGVNIVNPMSYL 
   FSDARIDKNKRRIAQINRQVTQNRNLIIKNNR 
QIVVTKRTQASLQSEINDLNFQINKLQKEYNVLE 
QRYIELLKAIGANEKDIKASISKIQSSNAEIKVNK 
DEYNTKIRNYDLIRRARNINQNSGLVGARRDKL 
RHDAHAILDLQINKIKGIETYKKGVEQDKIKVE 
GIKQKNQSEATKVMSARNDLENKKKELNTAV 
ARKNKAVAELRDLQNKLRKENITIEKNNSKLA 
SERNRLEAQINAIIRQNAIRQQQLERQRQLALRR 
KQQQGSAKHENINVSQEPINVVKGTGSLIYPIRG 
RVVVGFGTEKVQ 
 
 
 
 
Figure 3.9: Schematic representation of site specific degradation.  Peg 1 autodegrades itself 
at the  N terminus of the 12 kDa peptide. Cleavage occurs between Q335 and G336. Full amino acid 
sequence of signal peptide, N-terminus and C-terminus are noted below.  
 
49 
 
provides structural scaffolding. Laminin can also bind to collagen, integrins and other cellular 
domains.   
In addition to testing ECM components; we hypothesized that since this protease had 
homology to putative zinc endopeptidases that it must require zinc for activation. Therefore the 
substrates and Peg1 were incubated with varying amounts of salt concentrations. Fibronectin and 
laminin assays were run on SDS PAGE to determine if Peg1 was capable of complete 
degradation. Fibronectin and laminin substrates were collected from human tissue in attempt to 
recreate the in vivo substrates for Peg1. Fibronectin produced a band at 220kDa on the SDS 
PAGE and while it appeared that Peg1 was able to degrade fibronectin, complete degradation 
was never seen. While lanes 3 and 5 on the SDS PAGE gel appear to have less fibronectin 
(Figure 3.10), this might be due to salt concentrations effecting the migration of proteins into the 
gel. The fibronectin sample located in lane 4 was incubated with 5 mM ZnCl2 and 2mM CaCl2 
while lane 2 was incubated with three times more ZnCl2 and five times more CaCl2 
concentrations. The results indicate that less protein migrated into the gel which can be due to 
the salt concentration in the samples. Laminin produced two major bands at 50kDa and 130-
160kDa. Although the results of the SDS PAGE could indicate that the protease degrades the 
130-160 kDa peptide, once again it appears that the salt concentrations affected the migration of 
the protein into the gels (Figure 3.11). Furthermore, some of the samples remained in the wells. 
Therefore it was concluded that Peg1 cannot degrade fibronectin or laminin.  
 
Coagulase potential of Peg1  
 Several microorganisms are capable of producing coagulase enzymes to convert 
fibrinogen to fibrin which results in blood clotting, like S.aureus. This conversion is viewed as a  
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Figure 3.10: SDS PAGE fibronectin degradation assay.  Imperial stained SDS- PAGE. Lane 
2: Fibronectin+15mMZnCl2+10mM CaCl2, Lane 3: Fibronectin+ 15mM ZnCl2+ Peg1 , Lane 4: 
Fibronectin+5mMZnCl2+2mM CaCl2, Lane 5: Fibronectin+5mMZnCl2+ (1:5) Peg1, Lane 6: 
Peg1 alone. Degradation of Fibronectin is not seen.  
 
 
 
37 kDa  
250 kDa  
50 kDa  
Lane                                 2        3       4        5                       6 
Peg1                                 -        +        -        +                       + 
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Figure 3.11: SDS PAGE laminin degradation assay. Lane 2: Laminin+15mMZnCl2+10mM 
CaCl2, Lane 3: Laminin+ 15mM ZnCl2+ Peg1 , Lane 4: Laminin+5mMZnCl2+2mM CaCl2, Lane 
5: Laminin+5mMZnCl2+Peg1, Lane 6: Laminin + 5mMZnCl2+ (1:5) Peg1, Lane 7: Peg1 alone. 
Peg1 is unable to degrade laminin.  
50 kDa 
37 kDa 
Lane                                    2       3       4          5       6                       7    
Peg1                                    -       +        -         +       +                       + 
150 kDa 
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virulence factor since it coats the bacterial surface with fibrin and therefore can protect the 
bacterial cell from phagocytosis (Tortora et al., 2013).  Peg1 was incubated with rabbit 
fibrinogen; however, clumping never occurred and therefore Peg1 was not identified as a 
coagulase. This experiment was done to determine if Sn35 utilizes Peg1 to remain undetected 
from the immune system while traversing the fetal membranes. 
 
Analysis of cytotoxicity of Peg1 to ME-180s 
 Previous studies indicated that Sneathia amnii is cytotoxic to ME-180 cells which are 
cervical epithelial carcinoma cells. It is thought that the cytotoxic activity may help the bacteria 
ascend into the intrauterine cavity.  While Peg1’s peptides were analyzed through Edman 
degradation, a cytotoxicity assay was performed based upon Bacteriodes fragilis’s zinc 
endopeptidase’s capability to disrupt tight junctions in epithelial cell monolayers. Hypothesizing 
that Peg1 could have similar enzymatic capabilities; ME-180 cells were incubated with Peg1 and 
ZnCl2.  Results indicated that there was a significant increase in cell rounding compared to cells  
just treated with ZnCl2 (Figure 3.12). While obvious cytotoxicity was not seen, the monolayers 
incubated with Peg1 and ZnCl2  sloughed off.  
 
Analysis of biofilm formation capability of Peg1  
 Previous attempts to uncover Peg1’s protease capabilities indicated that Peg1 did not 
have true degradation of substrates utilized in this study. Therefore, it was hypothesized that 
Peg1 could be a ligand involved in adhesion and biofilm formation. Collagen type IV, which is 
located in the fetal membranes, was utilized to determine whether Peg1 could bind to collagen 
type IV and allow S.amnii to produce biofilms.  Live S.amnii was incubated in collagen type IV  
53 
 
 
 
 
 
 
 
Figure 3.12: Cytotoxic effect of Peg1 on ME-180s.  Monolayer exposed to ZnCl2, top image, 
remained intact and cells had little to no rounding. Monolayer exposed to Peg1 and ZnCl2, 
bottom image, came apart and sloughed off. An increase in cell rounding was observed when 
cells were exposed to Peg1.  
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strip wells with or without the addition of cleaved purified Peg1. After, the wells were stained 
with safranin to visually evaluate biofilm formation. No biofilm formation occurred in the 
presence or absence of Peg1.   
 
Bacteriolytic Activity 
 Production of a bacteriolysin is a virulence factor for the bacterial cell against other 
species. While autolysins are produced during binary fission to break down the bacteria’s own 
peptidoglycan layer and allow for two cells to form from one cell. We hypothesized that Peg1 
could be either a bacteriolysin or an autolysin since proteases, like proteinase K, can break down 
Micrococcus luteus. M23 peptidase family also contains endopeptidases that lyse bacterial cell 
wall peptidoglycans. The cleaved purified protease was exposed to Micrococcus luteus and a 
zymogram assay was performed. A zone of clearing was produced and therefore it was 
concluded that Peg1 appeared to have bacteriolytic activity. (Figure 3.13). When the cleaved 
purified protease was incubated with Sn35 to analyze autolysin potential via OD600nm 
measurement it was concluded that Peg1 was not capable of autolysin activity since there was 
not a significant decrease in OD600nm measurement. 
 
Collagen degradation 
 Collagen, an integral protein of connective tissue, is found in the ECM, skin, tendons, 
ligaments and other tissues. Collagen exists as procollagen before it is cleaved by proteases to 
allow for assembly into collagen; collagen type IV is the only type of collagen to be found in the 
basement membrane which is found in the fetal membranes. It had previously appeared that 
Sn35 had collagenase activity and could partially degrade collagen type V.  To analyze if Peg1  
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Figure 3.13: Bacteriolytic effect of Peg1 on Micrococcus lutues.  M. luteus embedded SDS 
was run and imperial stained to indicate whether or not Peg1 was able to lyse other bacterial 
species. A zone of clearing was observed in lanes 2-4 where Peg1 was loaded. Therefore Peg1 
appears to have bacteriolytic activity.   
 
 
 
 
 
                                      Proteinase K                                                                                                       +             +  
                                                  Peg 1    +            +              +                                                    
56 
 
 
was able to degrade collagen, collagen type IV and I were biotinylated and incubated with cleave 
purified Peg1. Western analysis indicated that Peg1 appears to have the same effect on collagen 
type IV as live bacteria do (Figure 3.14). Peg1 appears to have collagenase activity. 
 
 
Analysis of Peg1 antisera production 
 Bioinformatic analysis of PSORTb identified Peg1 as a lipoprotein located on the outer 
membrane of the bacterial cell wall. Additionally, PSORTb identified that without the 12kDa 
fragment the protein had no signal. Therefore cleaved purified protein was used for polyclonal 
antisera production to further help characterize Peg1. To confirm PSORTb results, live Sn35 was 
probed with anti-sera; however, western analysis indicated that Peg1 was not found on the 
outermembrane (Figure 3.15) and instead antisera detected the protein in the cytoplasm. While 
we hypothesized that the protease was expressed on the outermembrane and PSORTb indicated 
the same results, the results from western analysis cemented that this protease is not expressed on 
the outermembrane. To better understand the protease using antisera, a temporal expression 
assay was done to identify when the putative protease is expressed. The growth curve assay 
indicated that Peg1 is expressed throughout exponential phase, late exponential phase and 
stationary phase; hours 4 through 48(Figure 3.16).  
 
Discussion, Conclusion, and Future Perspectives 
Almost nothing is known about the process through which  S.amnii causes preterm birth, even 
though this newly discovered bacterium is associated with serious health complications for  
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Figure 3.14: Role of Peg1 in collagen degrdation. Lanes 1 and 2 are live Sn35 incubated with 
collagen type IV, lanes 3 and 4 are PBS incubated with collagen type IV, lanes 5 and 6 are Peg1 
incubated with collagen type IV. Peg1 appears to have collagenase activity, to the same effect 
that live Sn35 does.   
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Figure 3.15: Western analysis of Peg1 expression location.  Lane 1: molecular weight marker, 
Lane 2: cytosolic proteins of Sn35, Lane 3: outermembrane protein of Sn35.  Peg1 is visualized 
in the cytoplasm of Sn35 about 75 kDa.  
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Figure 3.16: Temporal expression of Peg1.  Lane 1: ladder, Lane 2: empty, Lanes 3-9 are cell 
lysates taken at 4,6,8,12,16,24,48 hours respectively. Peg1 expression was found throughout 
exponential, late exponential and stationary phase. Peg1 is visualized ~75 kDa.  
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both mother and neonate. We have hypothesized that S.amnii has virulence determinants that 
allow for the bacterium to traverse the fetal membranes and invade the amniotic cavity. The goal 
of this project was to identify a potential virulence factor that Sn35 utilizes to traverse the fetal 
membranes and cause preterm birth. We sought to first better understand traversal of S.amnii  
through the fetal membranes and then to explore potential virulence determinants that aided in 
the degradation of the extracellular matrix. The initial study focused on bacterial adhesion and 
ascension through the chorion layer to support MIAC. We have developed a method that 
simulates MIAC in vitro, and indicated that Sn35 is able to invade and traverse the chorion layer. 
These observations are significant because it supports bacterial ascension and indicates that 
S.amnii utilizes virulence determinants to ascend. The lack of detectable bacteria below the 
placental tissue indicates that further work is needed to develop a MIAC assay that can stay 
viable longer than 24 hours to observe microbial traversal. While Sn35 did not produce a strong 
ligand: ligand interaction with VK2 cell line, this indicates that further work is necessary to 
identify what cell tissue type Sn35 targets for cell adhesion. 
  The virulence determinants of S.amnii remain elusive. Analysis of its genome indicated 
promising virulence determinants that could enlighten its ability to traverse the fetal membranes 
and cause preterm birth.  We hypothesized that the putative zinc endopeptidase, Peg1, would 
degrade substrates found in the fetal membranes due to its homology to matrix 
mellatoproteinases. We attempted to discover Peg1’s degradation properties by incubating the 
cleaved purified protein with various substrates found in the extracellular matrix, like fibronectin 
and laminin; however, results from each experiment either did not support the hypothesis of 
degradation. Peg 1, under the conditions tested, was not capable of degrading casein, mucin, 
gelatin, or fibrinogen. Furthermore, Peg1 lacked biofilm formation capability using collagen type 
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IV as the substrate.   However, when Peg1 was incubated with collagen type IV, Peg1 appeared 
to have the same effect on collagen as the live bacteria. It appears that Peg1 has collagenase 
activity. Peg1 also appeared to have bacteriolytic activity against Micrococcus luteus which is 
characteristic of the M23 peptidase family. Antisera production of Peg1 identified the protease as 
being cytosolic, disproving PSORTb bioinformatic analysis that placed Peg1 on the 
outermembrane. Peg1 does appear to have protease activity, however, the conditions in which 
the protease is secreted where not found. Further work needs to be devoted to understand the 
conditions in which Peg1 is secreted.  
Peg1 appeared to autodegrade and we determined the cleavage site by Edman 
degradation.  Peg1 required the addition of CaCl2 in order to remain an intact peptide of 46.1 
kDa. If CaCl2 was not supplemented to the thrombin reaction, Peg1, underwent autocatalytic 
cleavage. This autocatalytic degradation resulted in two distinct peptides; a peptide sized 34.12 
kDa while the other 11.98 kDa. Further identification of the autocatalytic event was examined 
through N-terminal Edman degradation revealing that site specific cleavage occurred between 
Glutamine (335) and Glycine (336). Additionally, the cleavage at a glycine residue is often seen in 
M23 peptidase family, since it is the preferred sight of cleavage.  
Given the clinical complications that Sneathia amnii possesses as an opportunistic 
pathogen responsible for an array of infections in numerous body sites in both mother and 
neonate, research into the virulence determinants could have a significant impact of our 
understanding in their role in BV, MIAC, PPROM and preterm birth. The mucus plug and fetal 
membranes are supposed to remain impermeable until the end of gestation; however, S. amnii 
can be found in the uterine cavity, fetal membranes, and amniotic fluid during gestation. The 
work in this study revealed the ability of Sn35 to traverse the chorion layer of the fetal 
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membrane. Additionally it appears that Peg1 has collagenase and bacteriolytic activity that could 
be responsible for MIAC; however, conditions in which Peg1 is secreted were not identified.  
Therefore, the contributions of this study to our understanding of Sn35’s ability to cause preterm 
birth may help understand its other virulence determinants.  
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